2/20
07:27 am
catx
Perspective Therapeutics (NASDAQ:CATX) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Neutral
Report
Perspective Therapeutics (NASDAQ:CATX) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
2/19
07:07 am
catx
Perspective Therapeutics (NASDAQ:CATX) was given a new $16.00 price target on by analysts at Piper Sandler. They now have an "overweight" rating on the stock.
Medium
Report
Perspective Therapeutics (NASDAQ:CATX) was given a new $16.00 price target on by analysts at Piper Sandler. They now have an "overweight" rating on the stock.
2/17
11:17 am
catx
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
Low
Report
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
2/17
07:00 am
catx
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
Low
Report
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results
2/2
08:35 am
catx
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
High
Report
Perspective Therapeutics Announces Pricing of $175 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
1/30
10:04 am
catx
Perspective Therapeutics (NASDAQ:CATX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
Medium
Report
Perspective Therapeutics (NASDAQ:CATX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $11.00 price target on the stock.
1/30
07:17 am
catx
Perspective Therapeutics (NASDAQ:CATX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Perspective Therapeutics (NASDAQ:CATX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/13
08:03 am
catx
Perspective Therapeutics (NASDAQ:CATX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $14.00 price target on the stock.
Low
Report
Perspective Therapeutics (NASDAQ:CATX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $14.00 price target on the stock.
1/12
07:00 am
catx
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
High
Report
Perspective Therapeutics Provides Business Updates and Strategic Priorities Ahead of Presentation at 44th Annual J.P. Morgan Healthcare Conference
1/9
07:00 am
catx
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
Low
Report
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial at the 2026 ASCO Gastrointestinal Cancers Symposium
12/18
07:00 am
catx
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Perspective Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/4
07:00 am
catx
Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium
High
Report
Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium